Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 24

Sort by

Sort Order Select

Journal Articles

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

Mael Heiblig, Clement Gourguechon, Philippe Guilpain, Cristina Bulai Livideanu, Stéphane Barete, Julie Agopian, Fabienne Brenet, Patrice Dubreuil, Richard Lemal, Olivier Tournilhac, Louis Terriou, David Launay, Laurence Bouillet, Gandhi Laurent Damaj, Thomas Ballul, Céline Greco, Laura Polivka, Laurent Frenzel, Cecile Meni, Hassiba Bouktit, Caroline Gaudy-Marqueste, Marie Gousseff, Edwige Le Mouel, Antoine Neel, Dana Ranta, Roland Jaussaud, Thierry Jo Molina, Julie Bruneau, Ludovic Lhermitte, Marie Temple, Olivier Kosmider, Rose-Marie Javier, Fabien Pelletier, Florence Castelain, Frédérique Retornaz, Quentin Cabrera, Patricia Zunic, Marie-Pierre Gourin, Ewa Wierzbicka-Hainaut, Jean-Francois Viallard, Christian Lavigne, Cyrille Hoarau, Isabelle Durieu, Sophie Dimicoli-Salazar, Jose-Miguel Torregrosa-Diaz, Angele Soria, Michel Arock, Christine Bodemer, Olivier Lortholary, Olivier Hermine, Julien Rossignol

Blood (2023) 142 (Supplement 1): 1837.

https://doi.org/10.1182/blood-2023-185890

Published: 2023

Journal Articles

GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness

Julie Agopian, Quentin Da Costa, Quang Vo Nguyen, Giulia Scorrano, Paraskevi Kousteridou, Min Yuan, Rabie Chelbi, Armelle Goubard, Remy Castellano, Julien Maurizio, Cristina Teodosio, Paulo De Sepulveda, John M. Asara, Alberto Orfao, Olivier Hermine, Patrice Dubreuil, Fabienne Brenet

Blood (2021) 138 (17): 1590–1602.

https://doi.org/10.1182/blood.2020008948

Published: 2021

Includes: Supplemental data

Journal Articles

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Danielle Canioni, MD, Josquin Moraly, MD, Ludovic Lhermitte, MD PhD, Laura Polivka, MD, Mélanie Féroul, Julien Rossignol, MD PhD, Laurent Frenzel, MD PhD, Michel Arock, pharmD, PhD, Patrice Dubreuil, PhD, Leila maouche-Chretien, PhD, Olivier Hermine, MD PhD

Blood (2019) 134 (Supplement_1): 1683.

https://doi.org/10.1182/blood-2019-131256

Published: 2019

Journal Articles

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

Martine Humbert, PhD, Armelle Goubard, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 2075.

https://doi.org/10.1182/blood-2019-122540

Published: 2019

Journal Articles

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

Armelle Goubard, PhD, Martine Humbert, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 5142.

https://doi.org/10.1182/blood-2019-127143

Published: 2019

Journal Articles

AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes

Armelle Goubard, PhD, Martine Humbert, PhD, Colin Mansfield, PhD, Olivier Hermine, MD PhD, Patrice Dubreuil, PhD, The AB8939 Study Group

Blood (2019) 134 (Supplement_1): 5154.

https://doi.org/10.1182/blood-2019-127021

Published: 2019

Journal Articles

Recurrent TET2 Mutations in Adult T Cell Leukemia (ATL) and Identification of a Single Nucleotide Polymorphism in TET2 Region Predisposing to ATL Development

Ambroise Marçais, MD, Katia Hanssens, Laetitia Waast, Vahid Asnafi, MDPhD, Philippe Gaulard, MD PhD, Felipe Suarez, MD PhD, Laurence Benit, Patrice Dubreuil, Antoine Gessain, Claudine Pique, Olivier Hermine

Blood (2015) 126 (23): 3916.

https://doi.org/10.1182/blood.V126.23.3916.3916

Published: 2015

Journal Articles

Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma

Olivier Hermine, Ambroise Marçais, MD, Thiago Maciel, J Bagbor, Darius Jagielski, VMD, Nadine Holtermann, VMD, Elena Martinez de Merlo, VMD, Douglas H. Thamm, VMD, Patrice Dubreuil, PhD, Alain Moussy, MBA

Blood (2015) 126 (23): 3993.

https://doi.org/10.1182/blood.V126.23.3993.3993

Published: 2015

Journal Articles

Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis

Blood (2015) 126 (8): 1009–1016.

https://doi.org/10.1182/blood-2014-12-614743

Published: 2015

Includes: Supplemental data

Journal Articles

Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison

Blood (2014) 124 (21): 3193.

https://doi.org/10.1182/blood.V124.21.3193.3193

Published: 2014

Journal Articles

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Blood (2014) 124 (1): 111–120.

https://doi.org/10.1182/blood-2013-10-534685

Published: 2014

Includes: Supplemental data

Journal Articles

Mast cell leukemia

Sophie Georgin-Lavialle, Ludovic Lhermitte, Patrice Dubreuil, Marie-Olivia Chandesris, Olivier Hermine, Gandhi Damaj

Blood (2013) 121 (8): 1285–1295.

https://doi.org/10.1182/blood-2012-07-442400

Published: 2013

Journal Articles

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

Erinn Soucie, Katia Hanssens, Thomas Mercher, Sophie Georgin-Lavialle, Gandhi Damaj, Cristina Livideanu, Maria Olivia Chandesris, Yolène Acin, Sebastien Létard, Paulo de Sepulveda, Olivier Hermine, Olivier A. Bernard, Patrice Dubreuil

Blood (2012) 120 (24): 4846–4849.

https://doi.org/10.1182/blood-2011-12-397588

Published: 2012

Includes: Supplemental data

Journal Articles

Blood CD34 − c-Kit + cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor

Sophie Georgin-Lavialle, Ludovic Lhermitte, Cédric Baude, Stéphane Barete, Julie Bruneau, Jean-Marie Launay, Marie-Olivia Chandesris, Katia Hanssens, Christian de Gennes, Gandhi Damaj, Fanny Lanternier, Mohamed Hamidou, Olivier Lortholary, Patrice Dubreuil, Frédéric Feger, Yves Lepelletier, Olivier Hermine

Blood (2011) 118 (19): 5246–5249.

https://doi.org/10.1182/blood-2011-02-335950

Published: 2011

Journal Articles

Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients

Olivier Hermine, MD, PhD, Isabelle Hirsh, Gandhi Damaj, MD, Catherine Granpeix, Stéphane Barète, Felipe Suarez, Olivia Chansderis, David Ghez, Richard Delarue, Fanny Lanternier, Benedicte Deau, MD, Helene Coignard, Sylvie Fraitag, Danielle Canioni, MD, Philippe Casassus, MD, Patrice Dubreuil, Olivier Lortholary

Blood (2010) 116 (21): 1982.

https://doi.org/10.1182/blood.V116.21.1982.1982

Published: 2010

Journal Articles

Pediatric mastocytosis–associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations

Ying Yang, Sébastien Létard, Laurence Borge, Amandine Chaix, Katia Hanssens, Sophie Lopez, Marina Vita, Pascal Finetti, Daniel Birnbaum, François Bertucci, Sophie Gomez, Paulo de Sepulveda, Patrice Dubreuil

Blood (2010) 116 (7): 1114–1123.

https://doi.org/10.1182/blood-2009-06-226027

Published: 2010

Includes: Supplemental data

Journal Articles

Wide Range Sequencing of FLT3 Reveals a New Activating Mutation Associated with a Decreased Sensitivity to Tyrosine Kinase Inhibitors in Acute Myeloid Leukaemia.

Philippe Garrigue, Pharm, D, Thomas Prebet, MD, Sébastien Létard, PhD, Katia Hanssens, BSc, Wolfgang Sippl, PhD, Anne Lermet, PhD, Norbert Vey, Jean Paul Borg, PharmD, PhD, Patrice Dubreuil, PhD

Blood (2009) 114 (22): 3982.

https://doi.org/10.1182/blood.V114.22.3982.3982

Published: 2009

Journal Articles

The tyrosine kinase FES is an essential effector of KIT D816V proliferation signal

Edwige Voisset, Sophie Lopez, Patrice Dubreuil, Paulo De Sepulveda

Blood (2007) 110 (7): 2593–2599.

https://doi.org/10.1182/blood-2007-02-076471

Published: 2007

Journal Articles

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells

Blood (2006) 108 (3): 1065–1072.

https://doi.org/10.1182/blood-2005-06-2433

Published: 2006

Journal Articles

Phenotypic and Genotypic Characteristics of Mastocytosis Differ According to the Age of Disease’s Onset.

Fanny Lanternier, MD, Annick Cohen-Akenine, PhD, Fabienne Palmerini, PhD, Frederic Feger, MD, Laurent Nasca, PhD, Stephane Barete, MD, David Guez, MD, Philippe Casassus, MD, PhD, Christine Bodemer, MD, PhD, Michel Arock, MD, PhD, Patrice Dubreuil, MD, PhD, Olivier Hermine, MD, PhD, Olivier Lortholary, MD, PhD

Blood (2005) 106 (11): 3091.

https://doi.org/10.1182/blood.V106.11.3091.3091

Published: 2005

NARROW

Prognostic Characterization of Advanced Mastocytosis Patients Treated with Midostaurin According to Diagnosis and Mutation-Adjusted Risk Score: A Nation-Wide Ceremast Study of 170 Patients

GlcNAc is a mast-cell chromatin-remodeling oncometabolite that promotes systemic mastocytosis aggressiveness

BCL-2 Is Expressed in Advanced Mastocytosis and Midaustorin Induces Venetoclax Sensitivity of Mast Leukemia Cell Lines

Anticancer Activity of a Highly Potent Small Molecule Tubulin Polymerization Inhibitor, AB8939

In Vivo Assessment of the Next Generation Microtubule-Destabilizing Agent AB8939 in Patient-Derived Xenograft Models of Acute Myeloid Leukemia

AB8939, a Microtubule-Destabilizing Agent with Potential to Overcome Multidrug Resistance, Is Active across the Range (M0-M7) of Acute Myeloid Leukemia Subtypes

Recurrent TET2 Mutations in Adult T Cell Leukemia (ATL) and Identification of a Single Nucleotide Polymorphism in TET2 Region Predisposing to ATL Development

Development of Masitinib for the Treatment of Peripheral T-Cell Lymphoma

Long-term efficacy and safety of cladribine (2-CdA) in adult patients with mastocytosis

Treatment of Advanced Systemic Mastocytosis with PKC412: The French Compassionate Use Programme Experience and Historical Comparison

A new human mast cell line expressing a functional IgE receptor converts to tumorigenic growth by KIT D816V transfection

Mast cell leukemia

In aggressive forms of mastocytosis, TET2 loss cooperates with c-KITD816V to transform mast cells

Blood CD34 − c-Kit + cell rate correlates with aggressive forms of systemic mastocytosis and behaves like a mast cell precursor

Long Term Efficacy and Safety of Cladribine In Adult Systemic mastocytosis: a French Multicenter Study of 44 Patients

Pediatric mastocytosis–associated KIT extracellular domain mutations exhibit different functional and signaling properties compared with KIT-phosphotransferase domain mutations

Wide Range Sequencing of FLT3 Reveals a New Activating Mutation Associated with a Decreased Sensitivity to Tyrosine Kinase Inhibitors in Acute Myeloid Leukaemia.

The tyrosine kinase FES is an essential effector of KIT D816V proliferation signal

Rapamycin inhibits growth and survival of D816V-mutated c-kit mast cells

Phenotypic and Genotypic Characteristics of Mastocytosis Differ According to the Age of Disease’s Onset.

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only